Cargando…
APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions
In the realm of DNA repair, base excision repair (BER) protein, APE1/Ref-1 (Apurinic/Apyrimidinic Endonuclease 1/Redox Effector - 1, also called APE1) has been studied for decades. However, over the past decade, APE1 has been established as a key player in reduction-oxidation (redox) signaling. In t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457357/ https://www.ncbi.nlm.nih.gov/pubmed/34557865 |
_version_ | 1784571072565215232 |
---|---|
author | Mijit, Mahmut Caston, Rachel Gampala, Silpa Fishel, Melissa L. Fehrenbacher, Jill Kelley, Mark R. |
author_facet | Mijit, Mahmut Caston, Rachel Gampala, Silpa Fishel, Melissa L. Fehrenbacher, Jill Kelley, Mark R. |
author_sort | Mijit, Mahmut |
collection | PubMed |
description | In the realm of DNA repair, base excision repair (BER) protein, APE1/Ref-1 (Apurinic/Apyrimidinic Endonuclease 1/Redox Effector - 1, also called APE1) has been studied for decades. However, over the past decade, APE1 has been established as a key player in reduction-oxidation (redox) signaling. In the review by Caston et al. (The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease), multiple roles of APE1 in cancer and other diseases are summarized. In this Review, we aim to expand on the contributions of APE1 to various diseases and its effect on disease progression. In the scope of cancer, more recent roles for APE1 have been identified in cancer cell metabolism, as well as chemotherapy-induced peripheral neuropathy (CIPN) and inflammation. Outside of cancer, APE1 signaling may be a critical factor in inflammatory bowel disease (IBD) and is also an emergent area of investigation in retinal ocular diseases. The ability of APE1 to regulate multiple transcription factors (TFs) and therefore multiple pathways that have implications outside of cancer, makes it a particularly unique and enticing target. We discuss APE1 redox inhibitors as a means of studying and potentially combating these diseases. Lastly, we examine the role of APE1 in RNA metabolism. Overall, this article builds on our previous review to elaborate on the roles and conceivable regulation of important pathways by APE1 in multiple diseases. |
format | Online Article Text |
id | pubmed-8457357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-84573572021-09-22 APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions Mijit, Mahmut Caston, Rachel Gampala, Silpa Fishel, Melissa L. Fehrenbacher, Jill Kelley, Mark R. J Cell Signal Article In the realm of DNA repair, base excision repair (BER) protein, APE1/Ref-1 (Apurinic/Apyrimidinic Endonuclease 1/Redox Effector - 1, also called APE1) has been studied for decades. However, over the past decade, APE1 has been established as a key player in reduction-oxidation (redox) signaling. In the review by Caston et al. (The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease), multiple roles of APE1 in cancer and other diseases are summarized. In this Review, we aim to expand on the contributions of APE1 to various diseases and its effect on disease progression. In the scope of cancer, more recent roles for APE1 have been identified in cancer cell metabolism, as well as chemotherapy-induced peripheral neuropathy (CIPN) and inflammation. Outside of cancer, APE1 signaling may be a critical factor in inflammatory bowel disease (IBD) and is also an emergent area of investigation in retinal ocular diseases. The ability of APE1 to regulate multiple transcription factors (TFs) and therefore multiple pathways that have implications outside of cancer, makes it a particularly unique and enticing target. We discuss APE1 redox inhibitors as a means of studying and potentially combating these diseases. Lastly, we examine the role of APE1 in RNA metabolism. Overall, this article builds on our previous review to elaborate on the roles and conceivable regulation of important pathways by APE1 in multiple diseases. 2021 /pmc/articles/PMC8457357/ /pubmed/34557865 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Article Mijit, Mahmut Caston, Rachel Gampala, Silpa Fishel, Melissa L. Fehrenbacher, Jill Kelley, Mark R. APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions |
title | APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions |
title_full | APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions |
title_fullStr | APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions |
title_full_unstemmed | APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions |
title_short | APE1/Ref-1 – One Target with Multiple Indications: Emerging Aspects and New Directions |
title_sort | ape1/ref-1 – one target with multiple indications: emerging aspects and new directions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457357/ https://www.ncbi.nlm.nih.gov/pubmed/34557865 |
work_keys_str_mv | AT mijitmahmut ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections AT castonrachel ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections AT gampalasilpa ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections AT fishelmelissal ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections AT fehrenbacherjill ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections AT kelleymarkr ape1ref1onetargetwithmultipleindicationsemergingaspectsandnewdirections |